Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.40 |
| ▸ | HTR1D | P28221 | 8/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776549 | 1.00 | HTR1A (0.40) | HTR1AHTR1DCA2MAPTADRA2A | |
| SCHEMBL5722960 | 0.83 | HTR1A (0.40) | HTR1AHTR1DCA2ADRA2AADRA2B | |
| SCHEMBL5722961 | 0.83 | HTR1A (0.40) | HTR1AHTR1DCA2ADRA2AADRA2B | |
| SCHEMBL5777106 | 0.83 | HTR1A (0.41) | HTR1AHTR1DADRA2AADRA2BADRA2C | |
| SCHEMBL5723471 | 0.78 | HTR1A (0.60) | HTR1AHTR1D | |
| SCHEMBL5723477 | 0.78 | HTR1A (0.60) | HTR1AHTR1D | |
| Oxalic Acid SCHEMBL5774523 | 0.74 | HTR1A (0.58) | HTR1AHTR1D | |
| Cadaverine Tartrate SCHEMBL5723852 | 0.73 | HTR1A (0.53) | HTR1AHTR1D | |
| SCHEMBL5642484 | 0.71 | PER2 (0.41) | HTR1AHTR1DADRA2AADRA2BADRA2C | |
| SCHEMBL5722753 | 0.71 | RET (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036073-B1 | (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES HAVING FUNDIC RELAXATION PROPERTIES | JANSSEN PHARMACEUTICA NV (BE) | 2006-07-26 | — | — | EP | disclosed |
| US-6852714-B2 | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-08 | — | — | US | disclosed |
| US-6747045-B2 | SUCH AS 1-(3-(((3,4-DIHYDRO-2H-1-BENZOPYRAN-2-YL)METHYL) AMINO)-PROPYL)TETRAHYDRO-2(1H)-PYRIMIDINONE FOR TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-08 | — | — | US | disclosed |
| US-20030149093-A1 | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties | JANSSEN PHARMACEUTICA NV (BE) | 2003-08-07 | — | — | US | disclosed |
| US-20030083365-A1 | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-01 | — | — | US | disclosed |
| US-6495547-B1 | HAMPERED OR IMPAIRED RELAXATION OF THE FUNDUS TO FOOD INGESTION; IRRITABLE BOWEL SYNDROME, ANOREXIA, BLOATING, EARLY SATIETY, DYSPEPSIA | JANSSEN PHARMACEUTICA, N.V. (BE) | 2002-12-17 | — | — | US | disclosed |
| US-6133277-A | LITTLE OR NO VASOCONSTRICTOR ACTIVITY; GASTROINTESTINAL DISORDERS, E.G. DYSPEPSIA, EARLY SATIETY, BLOATING AND ANOREXIA; 1-(3-((3,4-DIHYDRO-2H-1-BENZOPYRAN-2-YL)METHYL)-AMINO)-PROPYL)-TETRAHYDRO -2(1H)-PRIMIDINONE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149093-A1 | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties | CBR1, CNR1, CNR2 | HTR1A 85/4885HTR1D 12/4885CA2 62/4885 |
| US-20030083365-A1 | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties | CBR1, CNR1, CNR2 | HTR1A 90/4885HTR1D 11/4885CA2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.